HJLI News and Press, Hancock Jaffe Laboratories Inc.

Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully comple...

Live webinar followed by Q&A on Monday, September 27 th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medic...

- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product for the treatment of veno...

Conference call with live video webcast to be held on Tuesday, September 21 st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vas...

Hancock Jaffe Laboratories develops nature-mimetic bioprosthetics for patients with debilitating cardiovascular diseases. The Company got IDE approval in April 2021 to begin a pivotal trial of VenoValve in the U.S. FDA granted Breakthrough Device Designation to the Company’...

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sc...

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occurred during the one-year r...

Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...

Zymergen (NASDAQ:ZY) -74% after forecasting no revenues this year, CEO exits Flora Growth (NASDAQ:FLGC) -15%. Tellurian (NASDAQ:TELL) -12% on Q2 earnings release and to offer shares; size not determined. LivePerson (NASDAQ:LPSN) -10% on Q2 earnings release. ...

Hancock Jaffe Laboratories (NASDAQ:HJLI) soars 39.6% premarket in reaction to the announcement that the FDA has granted Breakthrough Device Designation status to the VenoValve, the Company's lead product, which is currently set to begin its U.S. pivotal trial. The designation, akin ...